Displaying drugs 626 - 645 of 645 in total
IFx-Hu2.0
IFx-Hu2.0 is an investigational cancer vaccine. It is composed of plasmid DNA encoding the streptococcal membrane protein, Emm55, contained within a cationic polymer.
Investigational
Anti-SARS-CoV-2 REGN-COV2
Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of the antibodies REGN10933 and REGN10987, derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered...
Investigational
Matched Description: … [L14306]
Clinical trials for this drug started on June 11, 2020. …
COVID19 s-vax loaded autologous dendritic cell vaccine
Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors. These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine.
Dendritic Cells (DCs) are showing potential as natural adjuvants...
Investigational
Matched Description: … As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety …
SARS-CoV-2 Sclamp
The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in...
Investigational
Matched Description: … As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical …
BNT162b1 SARS-CoV-2 Vaccine
BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein together with a "foldon" trimerization domain derived from T4 fibritin...
Investigational
Matched Description: … [L15017, L15022] BNT162b1 received fast track designation by the FDA on July 13, 2020.[L15027] …
Dihomo-gamma-linolenic acid
A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.
Investigational
Nutraceutical
Matched Synonyms: … 20:3, n-6,9,12 all-cis …
Matched Description: … A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. …
Matched Description: … A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. …
RWJ-800088
RWJ-800088 is a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous TPO.
Investigational
Obexelimab
Obexelimab is under investigation in clinical trial NCT02725515 (A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus).
Investigational
Retlirafusp alfa
Investigational
Matched Synonyms: … monoclonal SHR-1316 .gamma.4-chain) fusion protein with peptide linker ((ggggs)4g) fusion protein with 20 …
Ersodetug
Investigational
Matched Synonyms: … gamma2 heavy chain Homo sapiens (1-444) [VH(Homo sapiens IGHV3-20*01 (98.0%) -(IGHD)-IGHJ6*01 (93.8%) …
VPM1002
The bacille Calmette-Guérin (BCG) vaccine protects against severe extrapulmonary forms of tuberculosis (TB) but does not adequately protect against pulmonary TB -- the most prevalent form of TB. This recombinant BCG, VPM1002, has been created in response and investigated for preventing pulmonary TB in newborns and TB recurrence in adults...
Investigational
Matched Description: … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
Palopegteriparatide
Palopegteriparatide is a mPEG conjugated parathyroid hormone 1-34.
Investigational
Matched Synonyms: … conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 …
Dabocemagene autoficel
Dabocemagene autoficel is an ex vivo, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen. Developed by Castle Creek Biosciences Inc., dabocemagene autoficel is being investigated for the treatment of dystrophic epidermolysis bullosa.
Investigational
ST-101
ST-101 is a small peptide antagonist of C/EBPβ and T-type calcium channel activator. ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer's Disease.
Investigational
Displaying drugs 626 - 645 of 645 in total